the 15th annual scrip awards · • credibility sells – winning this prestigious accolade is...

Scrip Awards 2019

The 15th AnnualScrip Awards

Entry Guide

4 December 2019 | London Hilton on Park Lane, London

www.scripawards.com

Sponsored by Headline Sponsor

Entry Deadline7 June 2019

http://www.scripawards.com

www.scripawards.comScrip Awards 2019

Introduction

Why Enter?

Entries are now open for the 15th Annual Scrip Awards. Since they began, the Scrip Awards has sought to applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare. Its trophies span the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising.

This year, we have introduced a new category – MSD’s Innovation Award – to acknowledge and celebrate the outstanding scientific or technological breakthroughs that have the potential to be transformative in the discovery or development of new medicines.

This is your chance to gain recognition for your hard work at an event full of industry professionals.

• Credibility sells – Winning this prestigious accolade is marketing that money can’t buy.

• Master your sector – Our awards cover activities across that the pharmaceutical, biotech and other allied industries, from start ups to big pharma.

• You don’t have to be big – You just have to be the best!

In addition, the Scrip Awards are FREE to enter! You have done the hard work, now all you need to do is convince the independent panel of experts judging this year’s awards.



Who Can Enter

How To Enter

The Scrip Awards is open to any research-based pharmaceutical or biotech company operating anywhere around the world, as well as to some third-party / partner companies that supply services to the pharmaceutical industry.

The Scrip Awards is free to enter.

1. Select the relevant category/ies for your business and review the entry criteria at scripawards.com

2. Complete the online entry form answering all questions, explaining why you or your company should be considered a winner this year. Please refer to the category criteria to guide your entry

3. Submit your entry by 7 June online via https://www.eventsforce.net/informabi/33/home (you will receive an automated submission receipt)

Please refer to the category criteria as a guide.

The Final Entry Deadline is 7 June 2019.

To discuss table bookings and event sponsorship please contact:Christopher KeelingTel: +44 (0) 20 337 73183Mobile: +44 (0) 7917 647 859Email: [email protected]

For general enquiries please contact:Lisa AnderbergTel: +44 (0) 20 755 19560Mobile: +44 (0) 7990 006621Email: [email protected]



• All entries must be written in English• All entries must be accompanied by a

250-word synopsis of the entry which may be used in Awards publicity material (this is in addition to the entry)

• All entries must be submitted via our online entry system

• All entries must be based on activities undertaken from activities undertaken since 1 June 2018 to 31 May 2019

• Answer each question under a separate heading, as specified in the category criteria

• Do not provide any supporting documentation – all information should

be included within your entry• Plan ahead to ensure it arrives in plenty

of time so that, should it be incomplete, there will still be time to correct and re-submit it before the closing date

• All entries will be treated as confidential, but Scrip reserves the right to publish positive extracts from winning entries

• All companies shortlisted as finalists will be notified directly by Scrip in September

• The judging panel reserve the right to move an entry into a different category if they feel it is better suited in this category

For this special Award, candidates must be nominated by a third party. The nomination should outline in no more than 750 words what the nominee has accomplished during his or her career and say why they are worthy of this Award.

All nominations must include:• The name of the nominee• The job title of the nominee (if applicable)• The company name (if applicable)• Your contact details• The contact details of the nominee• A précis of up to 750 words explaining

why you think your nominee is worthy of receiving the Lifetime Achievement Award

Entry GuidelinesEntry Deadline: 7 June 2019

Entering more that one Category

Lifetime Achievement Awards Nominations

Companies may enter more than one category, provided that each entry has been specifically written to address the relevant criteria and is accompanied by a separate 250-word synopsis.



Scrip Awards 2019 Categories

Masters Speciality Pharma’s Best Company in an Emerging Market Award

Scrip’s Best Company in an Emerging Market Award seeks to reward the growing R&D-based pharmaceutical industry founded in areas beyond its traditional geographic borders of North America, Western Europe and Japan.

This Award is open to any research-based pharmaceutical or biotechnology company that has its headquarters in an emerging market.

The judges will be looking for excellent performance across a range of business activities between June 1, 2018 and May 31, 2019. This could mean anything from growing sales and profits to launching new products, or signing a transformative new deal.

Companies eligible for this Award are those based in emerging markets in Asia, central and eastern Europe, central and south America, the Middle East and Africa.

To enter this category, please answer the following:• Please give the name of the entering company and country where it is headquartered.

• What has been this company’s most significant achievement during the year?

• Give details of what this company has achieved in terms of:

- Growth in sales and profits

- Signing important new deals

- Introducing new products onto the market

- Producing a promising new drug pipeline

- Operational improvements, particularly after restructuring, or changing the focus of the business.



Best Technological Development in Clinical Trials

The Scrip Award for Best Technological Development in Clinical Trials recognize the promising and disruptive role that digital health technology now plays in clinical drug development.

This Award recognizes the vital importance of using the most sophisticated technological developments to catalyze and optimize data gathered during clinical trials. Advances in software and applications have a pivotal role to play at all stages of the trial process, assisting in effective management of study logistics, monitoring, risk mitigation and timely data collection and analysis. The judges will be looking for the product or suite of products that help study teams better manage and oversee clinical trial activities.

All technologies launched or significantly updated between 1 June 2018 to 31 May 2019 are eligible to enter.

Companies wishing to enter must have played a role in the development of the nominated technology, and all parties to any joint development agreements should be disclosed in the application.

To enter this category, please provide the following:• The name of all companies involved in the product development, including an outline of

their role(s)

• Specify the date and market of the technology’s first launch or when it was significantly upgraded.

• Outline the key features and benefits of the technology, and how they support the clinical trial process

• What problems does this product solve and what is novel about it?

• What is the single most significant benefit of the entrant’s technology to users?

• Give an estimate of how much the technology could save a sponsor (in US$ or time) on a typical protocol compared with existing solutions

• If possible, please provide a link to a product demo (product webpage, YouTube video, etc.)



Community Partnership of the Year Award

This Award is designed to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community. This could include outreach within a local community, with a charity or patient advocacy group, or alongside an NGO or humanitarian organization.

The judges will be looking for effective partnership activity that took place between 1 June 2018 to 31 May 2019 to the benefit of humankind. Types of partnerships could include, for example, patient and carer support programs, educational programs or disease awareness campaigns or even a social media campaign that went viral.

To enter this category, please answer the following:• Please give the name of the entering company and the name of the partnership• Please outline the nature of the partnership being entered• What were the aims of the partnership?• What were the benefits of the partnership and how were they measured? • What lessons were learned from the partnership and how might it be improved in future?

MSD’s Innovation Award

This new category will acknowledge and celebrate the outstanding scientific or technological breakthrough that the judging panel believes has the potential to be transformative in the discovery or development of new medicines.

The award is open to any person, group or company that has achieved a genuinely ground-breaking advance during the qualifying period of 1 June 2018 to 31 May 2019. We welcome entries that are active in the life sciences ecosystem – from early-stage research through to clinical proof-of-concept developments.

Achievements we wish to recognize include: insights that advance our understanding of disease biology; new therapeutic targets or approaches; elucidation of a novel mechanism of action; clinical proof of concept of a novel mechanism or novel target; and techniques and technology platforms that enhance the medical benefits of new or existing medicines.

Entries will be judged on the answers to a number of key questions:• What is the scientific, technological or medical challenge they are targeting?• What is the solution to the challenge?• What proof of principle or concept have been achieved?• How will the entry impact either the discovery or development innovative therapeutic

approaches?• How novel is the innovation?



IQVIA’s Clinical Advance of the Year Award

This Award seeks to recognize success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.

Unlike the Best New Drug Award, the product involved need not yet be approved, but as with that award the judges will be looking for innovation, clear proof of benefit and potential commercial reward.

To be eligible, the study in question must have been presented for peer review at a major medical meeting or been published in a scientific journal between 1 June 2018 to 31 May 2019.

Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application.

To enter this category, please answer the following questions:• Please give full details of the study, i.e., its name (protocol ID, trial identifier), Phase,

disease type and patients segment studied, sponsors, and the primary drug tested

• Please summarize the major findings of the study, including all primary/co-primary and main secondary endpoints, and safety endpoints

• How does the drug work in the setting tested?

• How do these findings represent a potential leap forward in therapy, or fulfil an unmet medical need?

• What could be the potential market size of this breakthrough?



Financing Deal of the Year

This Scrip Award seeks to reward successful and creative fundraising by pharma and biotech companies. The investment can come in a variety of guises from grants and public-private partnership deals to venture fundraising and public offerings, but should be earmarked for use in drug discovery and/or development.

In making their decision, the judges will scrutinize entrants on their fundraising strategy, amount raised, the structure of the deal, and on how the money will be used. This Award is open only to companies actually raising the funds (i.e., not bankers or agents). To be eligible, all financing must have been announced between 1 June 2018 to 31 May 2019.

To enter this category, please answer the following questions:• Please outline the form of the financing, how much money was raised (including how

this compares with the company’s capital base), and how close was this to meeting your fundraising objectives?

• Please explain how this source of financing was best suited to your purposes

• Please describe how this fundraising was particularly creative. Has this set a precedent that has since been repeated?

• Did the funding succeed in other ways, such as bringing on board a new kind of investor?

• How will the money be used?

• Please give evidence of early value creation from the deal.



Licensing Deal of the Year – Sponsored by Worldwide Clinical Trials

Licensing is vital both in helping to keep pharma’s pipelines replenished and in generating income for smaller firms. Deals considered here are those that involve the licensing of a particular drug, project or group of drugs/projects from one company to another for further development and/ or marketing. (NB It does not include more involved partnerships between companies to explore particular therapeutic strategies (see criteria for the Best Partnership Alliance Award).)

In choosing the winner of Scrip’s Licensing Deal of the Year Award, the judges will look at all aspects of the submitted transactions, from their monetary and strategic value, to the benefits they give to both sides. To qualify, licensing deals must have been closed between 1 June 2018 to 31 May 2019.

To enter this category, please answer the following:• Please outline the structure of the deal, giving the names of the parties involved, the drug

candidate(s) concerned, and what rights it covers

• What is the monetary value of the deal in up-front and milestone payments?

• What is the geographic spread of the deal? Does it allow any party to enter new markets?

• What is the strategic value of the licensed product to the licensee’s business?

• Please explain how the licensed product was the best possible candidate to complement the rest of the licensee’s pipeline or particular disease franchise.

IMPORTANT NOTEWould your entry fit better in the Best Partnership Alliance category? Please consider before you enter.



Best Partnership Alliance

Scrip’s Best Partnership Alliance Award recognizes the importance of pharmaceutical and/or biotech companies working together to develop new medicines. This category seeks to reward innovative partnerships between companies in which they share the risks and rewards inherent in developing new drugs.

The judges will be focusing on deals that require strong strategic input from both partners, involving business development, joint marketing/promotion or joint R&D. They are looking for those deals that are the most mutually beneficial, have the most strategic potential, and are innovative in their structure.

Partnerships must have been announced, or have achieved a significant milestone, between 1 June 2018 to 31 May 2019 and entrants should be able to show some sustained benefits from the deal. NB: Deals between majority or wholly owned subsidiaries and their parent companies are not eligible for this Award.

To enter this category, please answer the following:• Please give the name of company/organizations involved

• Please outline the structure of the partnership, detailing the parties involved, what it covers and the responsibilities on both sides

• Does its structure represent an innovative business model, and if so how? How does it demonstrate that either party was the “partner of choice”?

• Please summarize the strategic potential of the deal, and if applicable the milestone reached

• Please explain how the deal is mutually beneficial to both parties

• What aspect of the deal makes it unique or particularly special?

• How does the collaboration hope to meet any unmet medical need?

IMPORTANT NOTEWould your deal fit better into the Licensing Deal of the Year category? Please check before you enter.



Business Development Team of the Year

Scrip’s Business Development Team of the Year Award will honor the achievements of business development teams whether they are from a pharma or biotech company or a cross-company team responsible for a specific deal or collaborative project.

This Award will go to a team that is truly much more than the sum of its parts. The judges will be looking for strong performance across a number of criteria, such as achievement of short and long-term goals, and good communication of a shared vision.

To enter this category, please answer the following:• Please give details of the company(ies), the particular team being entered and its core

function

• Please describe the team’s goals and vision, and how these are communicated

• What was the greatest achievement of the team during the year between 1 June 2018 to 31 May 2019?

• Please describe how all parts of the team were fully aligned to achieve this, including how supporting functions, such as HR, finance and IT, were integrated into the team

• Rate the team, giving justification, according to the following criteria:

- Achieving short-term and long-term goals

- Managing resources

- Providing a platform for professional development and teamwork

- How does the team embody a management model that others should follow?



Executive of the Year

Scrip’s Executive of the Year Award is designed to acknowledge excellence in the leadership of large and small pharmaceutical and biotechnology companies. This year’s winner will be the executive who has exhibited exemplary leadership throughout the year from 1 June 2018 to 31 May 2019.

This could range from leading an emerging company to an established place within the industry, to turning around the fortunes of a failing company or unit, or leading a firm successfully through the turbulence of a merger or acquisition. Also important to the judges will be the executive’s career achievements, influence within the industry and leadership qualities.

To be eligible for this year’s Award, entrants must hold a C-suite executive position. Candidates must be employed by the company at the time of nomination.

To enter this category, please answer the following:• Please give the name, company and position of the entrant, and the date of taking up this

post

• What have been the entrant’s greatest achievements during the qualifying year? What has been the direct consequence of these on company performance?

• How have these achievements strengthened the candidate’s influence within the industry? Please give examples

• What are the entrant’s greatest strengths as a leader? Please show how these have had a bearing on their achievements this year

• What specific previous accomplishments did the entrant have that made them perfectly fitted to achieving this success? For example, previous scientific or management experience.



Best Contract Research Organization – Full-Service Providers

The Scrip Awards for Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials.

This year the Award has been split into two categories to separate the full-service providers from those smaller CROs that provide specialist services to their clients.

Today, the role of the CRO has gone beyond the traditional model of service-level agreements to offer bespoke clinical trial strategies and CROs are increasingly engaged in risk-sharing partnerships or acting as a single-source developer while also remaining committed to core strengths.

This Award for those companies who provide the full range of services to their clients will be judged on the quality of services and relationships they have built with their clients. It will pay particular attention to the innovative patient recruitment strategies the CRO has brought to the deal.

To qualify, candidates must draw on their achievements in the year between 1 June 2018 to 31 May 2019.

To enter this category, please answer the following:• What particular capabilities and strengths does the CRO offer?

• How has this firm delivered results that exceed sponsor expectations?

• What innovations in patient recruitment strategy has the CRO brought to its partner?

• How has it improved its performance, for example, in its quality of data, timelines and transparency?

• What steps is the company taking towards streamlining data collection and reporting?



Best Contract Research Organization – Specialist Providers

The Scrip Awards for Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials.

This year the award has been split into two categories to separate the full-service providers from those smaller CROs that provide specialist services to their clients.

This Award for those companies who provide niche services to their clients will be judged on the quality of services and relationships they have built with their clients.

To qualify, candidates must draw on their achievements in the year between 1 June 2018 to 31 May 2019.

To enter this category, please answer the following:• What particular capabilities and strengths does the CRO offer?

• How has this firm delivered results that exceed sponsor expectations?

• What innovations has the CRO brought to its partner?

• How has it improved its performance, for example, in its quality of data, timelines and transparency?

• What steps is the company taking towards streamlining data collection and reporting?



WuXi AppTec’s Biotech Company of the Year Award

The biotech industry’s entrepreneurial spirit and cutting-edge science have transformed the research and development of medicines in the past few decades. This award honors outstanding achievement by biotech companies over the qualifying 12 months.

The winner of the Biotech Company of the Year Award will be the biotech firm that has achieved the most in the 12 months between 1 June 2018 to 31 May 2019. This could be in terms of moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.

To enter this category, please answer the following:• Name of entering company

• What has been the company’s most significant achievement during the year?

• Give details of what the firm has accomplished over the year in terms of:

- Bringing new products closer to their first markets

- Raising funds

- Signing significant licensing or partnership deals

- Showing strong management not afraid of making hard decisions

- Using proprietary science or technologies to address an unmet medical need

- Successfully transforming the business from an early stage to a more mature company



Syneos Health’s Best New Drug Award

The Best New Drug Award recognizes excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D.

In this category, the judges will be looking for the small-molecule or biological product that was approved in its first market worldwide during the qualifying period that represents the best therapeutic advance in its area.

All recently launched new active substances, including small-molecules, biologicals or vaccines, are eligible to enter as long as they were first licensed in any market between 1 June 2018 to 31 May 2019. Generic and biosimilar products are not eligible for this award.

Entrants must have played a role in the development of the nominated product, and all parties to joint ventures should be disclosed in the application.

To enter this category, please answer the following:• Please give the trade and generic name of the entrant, the therapeutic indication for which

it is being considered, and the company(ies) involved in its development (if more than one company, please detail the relationship between the parties)

• What was the date and market of the candidate’s first approval and launch?

• Please explain the mechanism of action of the candidate. How does this represent a step forward in treatment in this therapeutic area?

• Please outline the evidence for the product’s clinical activity. How does its activity translate into a meaningful therapeutic benefit for patients, and how is this benefit over and above that provided by other treatments in this area?

• How does the entrant address an unmet medical need?

• What is the potential market size of the candidate?



Pharma Company of the Year Award

The Pharma Company of the Year Award honors outstanding achievement by pharmaceutical companies over the qualifying 12 months, 1 June 2018 to 31 May 2019. This special award is chosen by Scrip’s senior editorial team, based on a variety of key metrics:

• Financial performance in 2018 compared with the previous year

• Strategic advances, looking at its most significant achievements over the year

• Progress in the emerging markets

• New product launches including line-extensions and formulations

• Advances in the drug pipeline, including major clinical trial reports.



Scrip’s Lifetime Achievement Award

The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career.

This prestigious international Award will go to someone who has had a distinguished career in the biotech or pharmaceutical arena, primarily within industry. Nominees may be retired or semi-retired but will still be active in the industry in some capacity. For this special Award, candidates must be nominated by a third party.

The nomination should outline in no more than 750 words what the nominee has accomplished during his or her career and say why they are worthy of this Award.

All nominations must include:• The name of the nominee

• The job title of the nominee (if applicable)

• The company name (if applicable)

• Your contact details

• The contact details of the nominee

• A précis of up to 750 words of why you think your nominee is worthy of receiving the Lifetime Achievement Award.



The Scrip Awards will culminate in a gala black-tie dinner and awards ceremony on Wednesday 4 December at the London Hilton on Park Lane. For security purposes, attendance at the event is by ticket only and guests are required to provide some personal details beforehand. All shortlisted companies and individuals are required to attend the Awards ceremony.

To discuss table bookings and event sponsorship please contact:

Christopher KeelingTel: +44 (0) 20 337 73183Mobile: +44 (0) 7917 647 859Email: [email protected] Or visit www.scripawards.com

• Read the entry details and judging criteria carefully for each category before starting your submission

• Write your entry specifically for the category in question, check the nomination is in the correct category and would not stand a better chance of winning in a different category

• Do not exceed the word limits. Entries should be 1,500 words, executive summaries 250 words, and there should be no supporting material

• Ensure the activities included were undertaken between the date parameters, 1 June 2018 to 31 May 2019

• Ensure each entry meets the specific criteria for its category

• Ensure you have answered each entry question under a separate heading in your submission

• Plan ahead to ensure it’s submitted in plenty of time so that, should it be incomplete, there will still be time to correct and re-submit it before the closing date of 7 June, 2019.

How Are The Scrip Awards Presented?

Useful Tips For A Winning Entry



Laura BrownDirector, LB Training and Development

Brown is an independent pharmaceutical project management, QA and training consultant, and course director for the MSc programme in clinical research at the University of Cardiff’s School of Pharmacy. She has more than 20 years of experience of managing clinical development projects, and training in the pharmaceutical industry. She has worked in project management for several companies including Wellcome, Hoechst Marion Roussel, Good Clinical Research Practices and LB Training and Development. She is also co-author of several books including, Project Management for the Pharmaceutical Industry.

Sir John Bell GBE, FRSRegius Professor of Medicine, Oxford University

Professor Sir John Bell GBE, FRS is Regius Professor of Medicine at Oxford University. He served as President of the Academy of Medical Sciences from 2006 to 2011 and chaired the Office for the Strategic Coordination of Health Research until 2017. As a Rhodes Scholar (1975-78), Sir John undertook his medical training in the UK and then went on to Stanford University, returning to the UK in 1987. His research interests are in the area of autoimmune disease and immunology where he has contributed to the understanding of immune activation in a range of autoimmune diseases. In 1993, he founded the Wellcome Trust Centre for Human Genetics, one of the world’s leading centres for complex trait common disease genetics. In 2001, he was appointed non-executive director of Roche Holding AG and in 2008 he joined the Gates Foundation Global Health Advisory Board which he has chaired since 2012. In December 2011, Sir John was appointed one of two UK Life Sciences Champions by the Prime Minister. He sits on the board of Genomics England Limited and chairs its Science Advisory Committee. He was appointed Knight Grand Cross of the Order of the British Empire (GBE) in the 2015 New Year Honours for services to medicine, medical research and the life science industry. In August 2017, the UK Life Sciences Industrial Strategy, written by Sir John, was published. The report, written in collaboration with industry, academia, charity, and research organisations, provides recommendations to HM Government on the long-term success of the life sciences sector.

Scrip Awards 2019 Judging Panel



Brian HargreavesIndependent Adviser, Consultancy

Hargreaves is an independent adviser for private equity. His career in healthcare spans academia, pharma, venture capital and private equity.

Following his early career as a lecturer in pharmacy at Manchester University, he had a series of commercial and international marketing roles with Smith Kline and French, Mundipharma, Wellcome, Glaxo Wellcome and with Astra Hässle which included the commercialisation of the blockbuster Nexium. In 1997, he moved to 3i plc in the innovative growth period of biotech venture capital. More recently he originated several significant growth capital deals and buyouts.

Hargreaves currently advises selected private equity firms and spends a proportion of his time in the charity sector.

Laurie A. HalloranPresident & CEO, Halloran Consulting Group, Inc.

Laurie founded Halloran Consulting Group in 1998 and has grown the business from a start-up to a highly regarded national consultancy with over 150 clients. These clients range from pre-funded startups who require regulatory and organizational growth strategies to global life science companies who need expertise managing product development challenges. She is able to draw additional expertise from her team in identifying and solving questions around strategy, regulatory, quality, organizational efficiency, complaint handling, human factors, manufacturing, medical affairs and compliance issues.

Earlier in her career, Halloran worked in the outsourcing services realm during PAREXEL International’s rapid growth phase. She later led clinical development at OXiGENE and Antigenics. Her advisory Board positions include Boston University’s School of Public Health, Leslie University Alumni Advisory Board, and Merck/EMD Serono’s Precision Medicine. She also serves on the New England Women in Science Executive’s Board of Directors.

Halloran has taught at George Washington University and Harvard University, and currently lectures at Boston University Medical School and the Tufts Center for Drug Development Post-Graduate program.



Annalisa Jenkins CEO, PlaqueTec

Dr. Annalisa Jenkins is a life sciences thought leader with over 20 years of biopharmaceutical industry experience. Prior to joining PlaqueTec CEO in November 2017, Jenkins served as president and CEO of Dimension Therapeutics,a leading gene therapy company that was acquired by Ultragenyx in November 2017. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years-including serving as senior vice president and head of global medical affairs. Earlier in her career, Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Jenkins is a board member of several growing companies, including Ardelyx, Inc., iOX Therapeutics Limited, Thrombolytic Strategies Incorporated, PhESi, Oncimmune, Cocoon Biotech Inc. (Non Executive Chair), Cellmedica (Non-Executive Chair), Vium, Inc.(Executive Chair), and Silence Therapeutics (Non-Executive Chair). She also is a committee member of the Science Board to the U.S. FDA, and serves on the board of the Center for Talent Innovation in the U.K.

Trevor M Jones CBEChairman, Simbec-Orion Group

Jones is chair of Simbec-Orion Group and Director Arix Bioscience plc. He was formerly R&D director of The Wellcome Foundation, a director of Allergan Inc. and director general of the Association of the British Pharmaceutical Industry (ABPI). He is a visiting professor at King’s College, London.



Alison MessomChairman, Institute of Clinical Research, Director ALM Consultancy

Since 2012, Messom has been chairman of the Institute of Clinical Research; the oldest independent membership-led professional body for global clinical researchers. With a background in molecular genetics, Messom has almost 20 years’ industry experience working both within pharmaceutical companies and clinical research organisations.

Messom has detailed experience of directing global clinical trials and has worked in a wide variety of leadership roles, within pharma companies and CROs not only for project and monitoring teams, but also data management, outsourcing, informatics and translational medicine departments. Most recently she has provided consultancy support to an academic group working on a translational medicine project and operational consultancy to a mid-sized pharma company working in Phase III and IV.

Viren MehtaFounder, Mehta Partners

Mehta founded and is managing member of Mehta Partners, LLC. His analytical insights on global healthcare have influenced bio-pharmaceutical strategy and investments worldwide. Educated at the University of Southern California and UCLA, he has worked with senior biopharma leaders and investment managers for over 30 years.

Mehta’s career began with Merck & Co. in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company Inc. to invite him to establish a pharmaceutical research function in New York. This effort was expanded at S.G. Warburg & Company, and led to the formation of the BioPharma investment advisory group Mehta and Isaly, now known as Mehta Partners.

Gather Health is Mehta‘s new initiative to empower patients while enhancing physician productivity. Gather Health brings together healthcare providers and patients’ social networks, enabling patients to get real-time and active resources and motivation to improve outcomes.



Peter PittsPresident, Center for Medicine in the Public Interest

Pitts is president of the Center for Medicine in the Public Interest. A former member of the United States Senior Executive Service, Pitts was the FDA’s associate commissioner for external relations, serving as senior communications and policy adviser to the commissioner. He supervised the FDA’s Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug taskforce and is a Special Government Employee consultant to the FDA’s Risk Communications Advisory Committee.

His specific areas of global policy expertise include FDA policy and process, healthcare technology assessment and reimbursement issues, real-world evidence, social media, off-label communications, pharmacovigilance, patient-focused drug development, abuse-deterrent opioids, biosimilar development, Rx-to-OTC switching, risk management plans, GMP policies, drug safety, Critical Path, personalized medicine, clinical trial transparency, IP protection, FDA reform, drug importation and counterfeiting.

Phornvit PhacharintanakulChairman, Strategic Business Partners

Phacharintanakul is chair of Strategic Business Partners in Bangkok, Thailand. Until the end of 2004 he was chair of the board at Aventis Thailand, where he previously held a range of posts including managing director and marketing manager. Before joining Aventis, he was on the secretariat of the United Nations Economic Commission for Asia and the Pacific. Phacharintanakul also acts as an expert advisor for the Thailand Center of Excellence for Life Sciences.



Rolf StahelChairman, Chesyl Pharma

Stahel worked for Wellcome Plc (now GlaxoSmithKline PLC) from 1967 to 1994, in Switzerland, Italy, Thailand, Singapore and the UK. He joined Shire Pharmaceuticals Group as chief executive officer in March 1994 and during his tenure implemented six mergers and acquisitions which in less than a decade transformed the private $30m company with $3m sales and 50 employees into a FTSE 100 company with a market capitalisation of about $3.2bn, revenues of $1.1bn and 1,800 employees. Since leaving Shire in 2003, he has been chairman and mentor for a series of biotech companies, including Jazz Pharmaceuticals (EUSA Pharma USA) Inc., Cosmo Pharmaceuticals NV, PowderMed Ltd., Midatech, Chesyl Pharma, Ergomed, Connexios Life Sciences, Norwood Immunology and Newron Pharmaceuticals.

Robert SpiegelFounder, Spiegel Consulting

Spiegel is the founder of Spiegel Consulting, an independent advisory firm to pharma and biotechnology companies. He retired in 2009 as chief medical officer at Schering-Plough. With more than 25 years of experience in the pharmaceutical industry he played a significant role in the development of novel biologics and drugs as senior vice-president of Worldwide Clinical Research. Spiegel is a fellow of the American College of Physicians and has received numerous awards and fellowships. He serves as an advisor to Warburg Pincus and the Israeli Biotech Fund and on the boards of numerous biotechnology companies and non-profit organizations. He is an assistant professor Weill Cornell Medical School and associate fellow in the University of Pennsylvania Center for Bioethics.



Brian TempestChair | Editor, Hale & Tempest Co Ltd | Journal of Generic Medicines

Tempest has worked in the pharmaceutical industry for the last 46 years and in that time has managed healthcare businesses around the globe. Between 1995 and 2007 he held senior executive positions, including president, CEO and vice-chairman at Ranbaxy Laboratories. Previously, Tempest was Far East regional director for GlaxoSmithKline in the Far East, Middle East and Africa. Today, as Chairman of Hale & Tempest, he advises companies, banks, investment funds, private equity and high net-worth individuals on their strategy in Asia. Tempest is a non-executive director of SRL Diagnostics, Fortis Healthcare, Touch Digital Media, Religare Capital Markets and Glenmark Pharmaceuticals. Currently he is Editor of theJournal of Generic Medicinesand a non-executive director of the United Nations Medicines Patent Pool.

Robert ThongIndependent Consultant and Writer, SciTechStrategy

Thong consults on business strategy and collaborations in the bioscience sector, and writes a regular blog on these topics, SciTechStrategy. Thong’s full-length book,Biopharma R&D Partnerships: From David & Goliath to Networked R&D, was published in January 2016, derived from the practical experiences of over forty different organisations. He has previously been co-head of the Cap Gemini Life Sciences Group, managing director of Datamonitor’s healthcare division, a non-executive board member of the listed US mid-sized pharmaceutical company Alpharma, and a co-founder of two specialist consultancies focusing respectively on mid-sized biopharma companies and change management for scientific organisations.



The Scrip Awards prides itself on its Judging Panel, comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility.

The judges separately consider entries from those categories that are relevant to their particular areas of specialist knowledge, expertise and experience, ensuring a considered response to every individual submission. Each category is reviewed by at least three judges.

The judges mark each entry against the published criteria for its category, and the scores are marked out of five for each category answer. These are then collated by the Scrip Awards team to determine which entries are included in the shortlist, and the ultimate winner.

The chair of the Judging Panel reserves the right to cast any deciding vote, should the need arise. The judges’ decision is final and neither the organisers nor the Judging Panel will enter into any correspondence about the results. Judging will take place throughout the summer, and the shortlist will be announced in September. Details of the winners are strictly embargoed until the night but further details of all of the shortlisted entries will be published in Scrip in the weeks leading up to the ceremony on Wednesday 4 December at the London Hilton on Park Lane.

How Do The Judges Select The Awards Winners?

Informa, organizer of the Scrip Awards, recognizes and respects the sensitive nature of the information submitted in the entries. We ensure that this recognition is shared by our Judging Panel and therefore require each judge to sign a confidentiality agreement before they are appointed. Entries are not disclosed or discussed outside the judging process. The Judging Panel for each Award is selected to avoid any conflict of interest. Once an entry is shortlisted, extracts from the entry summary only will be sourced for inclusion in the Awards ceremony and any subsequent editorial coverage. Please ensure your entry summary contains no confidential or sensitive information.

Confidentiality



Q. How do I enter?A. It’s very simple. Ensure you have read the entry guidelines and category criteria. Decide which category/

categories you wish to enter, and create your on-line account at https://www.eventsforce.net/informabi/33/home. Once you are ready click ‘Enter Now’, follow the onscreen instructions and submit your entry by clicking ‘Enter’.

Q. How much does it cost to enter?A. Entering the Scrip Awards is FREE of charge.

Q. When is the entry deadline?A. Entries are being accepted until 7 June 2019.

Q. I am not sure which category our entry would fit into?A. If you are not sure which category your entry fits into, please contact Lisa Anderberg at

[email protected] for further assistance.

Q. Can I enter the same submission into more than one category?A. We encourage entries in more than one category per individual or company, where appropriate; please

ensure to review the category criteria and tailor your entry accordingly.

Q. I am a sponsor of the awards am I still able to enter?A. Yes you can enter the awards. And we would encourage this, however you are unable to enter the category

you are sponsoring. But don’t worry there are plenty of other categories.

Q. How will I know whether my submission has been received?A. All submissions will be acknowledged by an automated email once you have submitted your entry. Our

awards team will also get in touch with you again shortly before the entry deadline. If you have any concerns, please contact Lisa Anderberg at [email protected]

Q. How will I know if my submission has been successful?A. Following the judging all companies and individuals will be notified by email. Finalists will be announced on

our website, www.scripawards.com. If you are successful, you will also receive an email from us on what happens next.

Q. What do I get if I win?A. The Scrip Awards are highly regarded within the industry and winning an award marks you out as a leader

in your field. In addition to your trophy and a certificate of recognition you will receive a winner’s pack with additional details on publicizing your success.

Q. How can I ensure I’m at the ceremony for the networking?A. It’s essential to book your place at the event. Please contact Christopher Keeling at

Tel: +44 (0) 20 337 73183 or Email: [email protected] for information.

Q. Are there other ways I can get involved in the awards?A. Yes, there are many sponsorship opportunities available. Please contact Christopher Keeling at

Tel: +44 (0)20 337 73183 or Email: [email protected] for information.

FAQ


https://www.eventsforce.net/informabi/33/home

https://www.eventsforce.net/informabi/33/home

Entry and General Enquiries:Lisa Anderberg

Tel: +44 (0) 20 7551 9560 | Email: [email protected]

Sponsorship and Table Booking Enquiries:Christopher Keeling, Sponsorship and Sales Manager

Tel: +44 (0) 20 3377 3183 | Email: [email protected]

Thank youEntry Deadline: 7 June 2019

Scrip Awards 2019

the 15th annual scrip awards · • credibility sells – winning this prestigious accolade is...

Documents